RxDoctor Payments Data

Andrew Billon, MD

Surgery · Indiana, PANPI 1922086131

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $103,300 of the $127,822 with a category attached, or 80.8%. Evologics LLC accounts for 98.9% of it on its own, with 25 other manufacturers making up the rest. Among surgery clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$127,822in general payments, 2019–2025

Across 83 payments — averaging $1540.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Evologics LLC$126K
  • Johnson & Johnson$256
  • Intuitive Surgical$137
  • Cumberland Pharmaceuticals, Inc.$137
  • W. L. Gore & Associates, Inc.$131
  • Ferring Pharmaceuticals Inc.$118
  • plus $633 from 20 others

What the payments were for

  • Royalty or licence$103,30081%
  • Consulting fees$23,11018%
  • Food & beverage$1,3681%
  • Education$180%
  • Entertainment$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$127,822 in reported general payments places this provider in the 95th percentile of 1,424 surgery providers in Pennsylvania.

See all surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$29,850
Medicare patients
119
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClenpiqSod Picosulf/Mag Ox/Citric Ac22$3,669
Sucralfate20$3,512
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg119$2,971
Pantoprazole Sodium272$2,798
Colesevelam Hcl11$1,940
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl18$317
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl12$209
Meloxicam11$11

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ferring Pharmaceuticals Inc.Clenpiq$118$3,66922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,424 surgery providers in Pennsylvania.

Other surgery in Indiana

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →